Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus Target Price from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $51.90.

A number of research firms have commented on TWST. Barclays cut their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday. They issued an “outperform” rating and a $60.00 price objective for the company.

Twist Bioscience Stock Up 2.0 %

Shares of NASDAQ TWST opened at $48.43 on Friday. The firm has a 50-day simple moving average of $45.06 and a 200-day simple moving average of $46.76. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -13.45 and a beta of 1.82. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,216 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. This represents a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paula Green sold 860 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares in the company, valued at $7,046,780.50. This represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,787 shares of company stock valued at $4,584,508 over the last 90 days. 3.92% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. State Street Corp grew its stake in shares of Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after purchasing an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter worth $43,992,000. Wellington Management Group LLP increased its holdings in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Finally, Fred Alger Management LLC raised its position in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after purchasing an additional 112,272 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.